Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Latest Information Update: 19 Jun 2024
At a glance
- Drugs Carboplatin (Primary) ; Elraglusib (Primary)
- Indications Adenoid cystic carcinoma; Carcinoma; Salivary gland cancer
- Focus Therapeutic Use
- 21 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 05 Dec 2023 Planned primary completion date changed from 1 Jan 2024 to 1 Jun 2024.
- 16 Oct 2023 Planned primary completion date changed from 30 Sep 2023 to 1 Jan 2024.